Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT01773187 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT01773187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01773187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2013
Completion date
April 30, 2016
Enrollment
327 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis